medigraphic.com
ISSN 0188-9796 (Print)

2002, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2002; 10 (3)

Adipo-pancreatic axis: A promising therapeutic approach for the preventions to insulin resistance and type 2 diabetes

Raúl Bastarrachea-Sosa, Hugo Laviada-Molina, Ildefonso Machado-Domínguez

Language: Spanish
References: 30
Page: 128-134
PDF size: 73.57 Kb.


ABSTRACT

The intracellular fatty acid binding proteins (FABPs) are a family of small cytoplasmic proteins that are expressed in a highly tissue-specific manner and can bind a single fatty acid molecule. The aP2 protein is a member of this family, expressed at high levels in the adipocytes. aP2 is an intracellular protein which functions in binding, shuttling and trafficking fatty acids through the aqueous cytosol in the adipocyte. Recent work has indicated an important in vivo role for this protein in lipid and glucose metabolism. Recent studies have also indicated that mice deficient for aP2 were shown to be protected from development of insulin resistance and hyperinsulinemia in a high fat diet-induced obesity model. The aP2-deficient mice developed dietary obesity but, unlike control mice, they did not develop insulin resistance or type 2 diabetes. This protection from developing insulin resistance due to diet-induced obesity in the absence of aP2, suggests that adipocyte fatty acid metabolism is a critical component of the mechanism leading to insulin resistance and type 2 diabetes. We will also provide support for the existance of an adipo-pancreatic axis, the proper action of which relies on the presence of aP2. Consequently, inhibition of aP2 is a promising therapeutic approach with potential indications for the treatment, or much better, for the prevention of the development of type 2 diabetes in the obese.


REFERENCES

  1. . Weyer C, Bogardus C, Mot DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 103: 253-259.

  2. Harris MI, Hadden WC, Knowler WC, Bennelt PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr. Diabetes 1987; 36: 523-534.

  3. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States 1991–1998. JAMA 1999; 282: 1519-1522.

  4. Must A, Spadano J, Coakley EH, Field AE, Colditz D, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.

  5. Bogardus C, Lillioja S, Howard BV. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in non-diabetic and non-insulin-dependant diabetic subjects. J Clin Invest 1984; 74: 1238-1244.

  6. Haffner SM, Stern MP, Hazuda HP. Increased insulin concentrations in nondiabetic offsprings of diabetic parents. N Engl J Med 1988; 319: 1297-1301.

  7. Knowler WC, Pettitt DJ, Savage PJ. Diabetes incidence in Pima Indians: contributions of obesity and parenteral diabetes. Am J Epidemiol 1981; 113: 144-149.

  8. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanisms of free fatty acid induced-insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.

  9. Crespin SR, Greenough 3rd WB, Steinberg D. Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect. J Clin Invest 1973; 52: 1979-1984.

  10. McGarry JD, Dobbins RI. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 126-138.

  11. Coe NR, Bernlohr DA. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1998; 1391: 287-306.

  12. Bernlohr DA, Simpson MA, Hertzel AV, Banaszak LJ. Intracellular lipid-binding proteins and their genes. Annu Rev Nutr 1997; 17: 277-309.

  13. Hotasmisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-1379.

  14. Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2) gene impairs fat cell lypolisis and increases cellular fatty acid levels. J Lipid Res 1999; 40: 967-972.

  15. Scheja L, Makowsky L, Uysal KT, Meyers DS, Morgan M, Parker RA, Hotamisligil GS. Altered insulin secretion associated with reduced lypolitic efficiency in aP2 (-/-) mice. Diabetes 1999; 48: 1987-1994.

  16. Teoman-Uysal K, Scheja L, Weisbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-3396.

  17. Hotamisligil GS, Spiegelman BM. TNF: a key component of obesity-diabetes link. Diabetes 1994; 43: 1271-1278.

  18. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992; 130: 43–52.

  19. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.

  20. Atgie C, D’Allaire F, Bukowiecki LJ. Role of beta-1 and beta-3 adrenoceptors i the regulation of lipolysis and thermogenesis in rat brown adipocytes. Am J Physiol 1997: 173: C1136-C1142.

  21. Londos C. Hormone-sensitive lipase and the control of lypolisis in adipocytes. In: Diabetes Mellitus: A Fundamental and Clinical Text. Le Roith D, Taylor SI, Olefsky JM, Eds. Philadelphia, PA, Lippincott-Raven, p. 1996; 223-227.

  22. Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ, Londos C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J Biol Chem 1991; 266: 11341-11346.

  23. McGarry JD. What if Minkowski had been ageusic? An alternative angle in diabetes. Science 1992; 258: 766-770.

  24. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.

  25. Bloom JD, Dutia MD, Johnson BD, Wissner A, Burns MG, Largis EE, Dolan JA, Claus TH. CL 316,243: a powerful beta adrenergic agonist virtually specific for beta 3 receptors: a promising antidiabetic and antiobesity agent? J Med Chem 1992; 35: 3081-3084.

  26. Granneman JG, Lahners KN, Chaudhry A. Molecular clonning and expression of the rat beta-3 adrenergic receptor. Mol Pharmacol 1991; 40: 895-899.

  27. Fain JN, Kovacev VP, Scow RO. Antilipolytic effect of insulin in isolated fat cells of the rat. Endocrinology 1996; 78: 773-778.

  28. Honnor RC, Dhillon GS, Londos C. cAMP-dependant protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation and predictability in behavior. J Biol Chem 1985; 260: 15122-15129.

  29. Grujic D, Susulic VS, Harper ME, Himms Hagen J, Cunningham BA, Corkey BE, Lowell BB. Beta 3-adrenergic receptors on white and brown adipocytes mediate B3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake: a study using transgenic and gene knock out mice. J Biol Chem 1997; 272: 17686-17693.

  30. Crespin SR, Greenough WBD, Steinberg D. Stimulation of insulin secretion by long-chain free fatty acids: a direct pancreatic effect. J Clin Invest 1973; 53: 1979-1984.




2020     |     www.medigraphic.com